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Impact of post-procedural glycemic 
variability on cardiovascular morbidity 
and mortality after transcatheter aortic valve 
implantation: a post hoc cohort analysis
Guillaume Besch1,2*†, Sebastien Pili‑Floury1,2†, Caroline Morel1, Martine Gilard3, Guillaume Flicoteaux1, 
Lucie Salomon du Mont4, Andrea Perrotti2,5, Nicolas Meneveau2,6, Sidney Chocron2,5, Francois Schiele2,6, 
Herve Le Breton7, Emmanuel Samain1,2 and Romain Chopard2,6
Abstract 
Background: Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of 
early glycemic variability after transcatheter aortic valve implantation is not known. This study was therefore designed 
to analyze the prognosis significance of post‑procedural glycemic variability within 30 days after transcatheter aortic 
valve implantation.
Methods: A post hoc analysis of patients from our center included in the FRANCE and FRANCE‑2 registries was 
conducted. Post‑procedural glycemic variability was assessed by calculating the mean daily δ blood glucose during 
the first 2 days after transcatheter aortic valve implantation. Major complications within 30 days were death, stroke, 
myocardial infarction, acute heart failure, and life‑threatening cardiac arrhythmias.
Results: We analyzed 160 patients (age (median [interquartile] = 84 [80–88] years; diabetes mellitus (n) = 41 (26%) 
patients; logistic Euroscore = 20 [12–32]). The median value of mean daily δ blood glucose was 4.3 mmol l−1. The rate 
of major complications within 30 days after procedure among patients with the lowest quartile of glycemic variability 
was 12%, increasing from 12 to 26%, and 39% in the second, third, and fourth quartiles, respectively. In multivari‑
ate analysis, glycemic variability was independently associated with an increased risk of major complications within 
30 days after the procedure (odds ratio [95% CI] = 1.83 [1.19–2.83]; p = 0.006).
Conclusions: This study showed that post‑procedural glycemic variability was associated with an increased risk of 
major complications within 30 days after transcatheter aortic valve implantation.
Trial registration Clinical trial registration number https ://www.clini caltr ials.gov/; identifier: NCT02726958; date: April 
4th, 2016
Keywords: Aortic disease, Transcatheter aortic valve implantation, Blood glucose, Glucose variability, Adverse events
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Cardiovascular Diabetology
*Correspondence:  gbesch@chu‑besancon.fr 
†Guillaume Besch and Sebastien Pili‑Floury contributed equally to this 
work
1 Department of Anesthesiology and Intensive Care, University Hospital 
of Besancon, 3 Boulevard Alexander Fleming, 25000 Besancon, France
Full list of author information is available at the end of the article
Page 2 of 9Besch et al. Cardiovasc Diabetol           (2019) 18:27 
Background
Glycemic variability, defined as the degree of blood 
glucose level excursion over time, is associated with 
an increase in critically ill patients in-hospital mortal-
ity and poor prognosis after acute coronary syndrome 
[1–3]. In cardiac surgery patients, glycemic variability 
was reported to be associated with severe postoperative 
complications, regardless of the quality of blood glucose 
control obtained during the perioperative period [4, 5]. 
Glycemic variability was also reported to be a significant 
predictor of the length of intensive care unit (ICU) stay 
and acute kidney injury after cardiac surgery [6]. The 
mechanisms underlying the deleterious effect of glyce-
mic variability include increased oxidative stress and 
endothelial dysfunction, and cell apoptosis [7, 8].
Transcatheter aortic valve implantation (TAVI) has 
emerged as a viable alternative to surgical aortic valve 
repair for patients with severe symptomatic aortic steno-
sis [9–11]. Although TAVI is not considered as a major 
surgical procedure, high post-procedure morbidity and 
mortality have been reported, mainly explained by the 
severe comorbidities presented by these patients [12, 13]. 
Although patient outcome after TAVI was not found to 
be different in diabetic and non-diabetic patients [14–16], 
Giannini et  al. [17]. have recently suggested that post-
procedural acute hyperglycemia increased the risk of 
acute kidney injury and was associated with higher mor-
tality after TAVI. The link between post-procedural gly-
cemic variability and outcome after TAVI is not known.
The purpose of this study was to investigate whether 
glycemic variability could be associated with an increased 
risk of major cardiovascular or cerebrovascular events or 
death within 30 days after TAVI.
Methods
Study design and setting
We conducted a posthoc analysis of a subgroup of 
patients included between February 2009 and June 
2012 at our institution in the multicenter FRANCE or 
the FRANCE-2 registries [18, 19]. The registries were 
approved by the Institutional Review Board of the 
French Ministry of Health. All patients provided written 
informed consent to have their data included in the reg-
istries. The present study was conducted in accordance 
with the Code of Ethics of the World Medical Association 
forth in the Helsinki Declaration of 1975 and with French 
bioethics law (Art. L. 1121-1 of the law no. 2004-806, 
August 9th, 2004). It was approved by the Institutional 
Review Board of the French Society of Thoracic and Car-
dio-Vascular Surgery (no. CERC-SFCTCV-2016-2-17-
17-18-2-BEGu, Chairperson Prof JL de Brux) on March 
12th, 2016. The study was registered on April 4th, 2016 at 
http://www.clini caltr ials.gov (Identifier: NCT02726958). 
This manuscript adheres to the applicable Strengthening 
the Reporting of Observational studies in Epidemiology 
(STROBE) guidelines.
Population of the study
Inclusion criteria for the FRANCE and FRANCE-2 reg-
istries were: (1) severe aortic stenosis, defined as an 
aortic valve area of < 0.8 cm2, a mean aortic-valve gradi-
ent ≥ 40 mmHg, or a peak aortic jet velocity ≥ 4.0 m s−1; 
(2) New York Heart Association (NYHA) class II, III, 
or IV symptoms; (3) non-eligibility for aortic surgery; 
and (4) aortic valve repair using TAVI. Eligibility of the 
patients for TAVI was assessed by a multidisciplinary 
team.
The choice of the TAVI device (self-expandable 
Medtronic CoreValve (Medtronic, Inc., Minneapolis, 
Minnesota, USA) or the balloon-expandable Edwards 
SAPIEN (Edwards Lifesciences, Irvine, California, USA), 
the route of implantation and the anesthetic protocol 
were left at the discretion of the physicians in charge 
of the patient. At the end of the procedure, all patients 
were admitted to the cardiac surgery ICU. Patients who 
suffered a major complication within the first 48 h after 
TAVI were excluded from the analysis.
Peri-procedural blood glucose management was per-
formed by a dynamic insulin therapy protocol [20]. 
Briefly, the rate of insulin infusion was adjusted accord-
ing to the current blood glucose value, the previous blood 
glucose value and the current rate of insulin infusion. All 
blood glucose values were obtained from glucose meter 
readings (Optium Xceed™, Abbott Diabetes. Care Ltd., 
Witney, UK) measured from an arterial blood sample 
taken from the indwelling arterial catheter. Blood glucose 
levels were checked hourly until 3 consecutive blood glu-
cose values were within the target range, then every 3 h 
Hourly blood glucose measurement was resumed if any 
of the following occurred: change in the rate of insulin 
infusion, change in clinical condition, initiation or cessa-
tion of vasopressor therapy or renal replacement therapy. 
The intravenous insulin infusion was replaced by subcu-
taneous insulin when oral feeding was initiated. The insu-
lin therapy protocol was managed by the nurses, and the 
medical team was consulted in case of severe hypoglyce-
mia or uncontrolled hyperglycemia.
Variables measurement
Baseline characteristics of patients and perioperative 
outcome data within 30 days after TAVI were extracted 
from the FRANCE and FRANCE-2 registries [18, 19]. 
For each patient, the number of blood glucose measure-
ments performed, the average blood glucose value, the 
percentage of blood glucose value within the range of 
4.4–8.2  mmol  l−1, the number of adjustments made in 
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the insulin infusion rate, and the rate of insulin therapy 
adjustment (defined as the ratio of the number of adjust-
ment made in the insulin infusion rate on the num-
ber of blood glucose measurements performed) were 
recorded during the first 48  h after TAVI. All patients 
spent the first 48  h after the procedure in the intensive 
care unit (ICU), and then, were discharged to the ward 
in the absence of complication. To allow for a homog-
enous measurement of glycemic variability, the observa-
tion period of the study was defined as the first 48 h after 
TAVI. Glycemic variability was assessed using the follow-
ing variables: (1) mean daily δ blood glucose, defined as 
the mean of the daily difference between the maximal 
and the minimal blood glucose value; [2] (2) standard 
deviation (SD) of blood glucose, defined as the SD of all 
blood glucose readings in a patient within the first 48 h 
after the procedure; and (3) the coefficient of variability 
of blood glucose level, expressed in percentage, defined 
as the ratio of the SD of blood glucose to the average of all 
blood glucose values * 100. The rate of moderate (blood 
glucose < 3.8 mmol  l−1) or severe (< 2.2 mmol  l−1) hypo-
glycemia [21], and the rate of hyperglycemia, defined as 
two consecutive blood glucose values ≥ 8.2  mmol  l−1 
were also recorded [17]. The insulin infusion rate vari-
ability was calculated from and expressed as the standard 
deviation of all insulin infusion rates per patient.
Endpoints
The primary endpoint was the rate of post-procedural 
major adverse events (MAEs) occurring between the 3rd 
and the 30th day after TAVI. This composite endpoint 
included death from all causes, stroke, myocardial infarc-
tion, acute heart failure, and life-threatening ventricular 
arrhythmias, according to the Valve Academic Research 
Consortium criteria [22]. The primary endpoint was 
established before statistical analysis on the basis of the 
primary hypothesis of the study. Secondary endpoints 
were: (1) the rate of each event composing the primary 
outcome, occurring during the same period; (2) the rate 
of the following complications: pulmonary embolism, 
post-procedural atrial fibrillation, pericardial tamponade, 
respiratory failure requiring mechanical ventilation, and 
acute renal failure (graded according to the Acute Kidney 
Injury Network classification [23]); and (3) the length of 
stay in the Cardiac Surgery ICU.
Statistical methods
The Shapiro–Wilk test was used to check whether quan-
titative data were normally distributed or not. Normally 
distributed data are presented as mean (SD), non-nor-
mally distributed data as median [interquartile range 
25%–75%], and qualitative data as a number of patients 
(percentage).
Comparisons between patients with and without MAE 
were performed using the Student t test and the Mann–
Whitney U-test for normally and non-normally distrib-
uted quantitative variables, respectively, and using the 
Chi square test for qualitative variables. The proportion 
of MAE in each quartile of the mean daily δ blood glu-
cose was compared by using a Chi square test for trend. 
Stepwise logistic regression was performed to model 
the risk of post-procedural MAE. The logistic regres-
sion model included variables with a p-value of < 0.20 
by univariate analysis comparing patients with and 
without post-procedural MAE (hypertension, obesity, 
New York Heart Association (NYHA) class III-IV, logis-
tic Euroscore), hyperglycemia (yes/no) and quartiles of 
the mean daily δ blood glucose. The mean daily δ blood 
glucose was used to measure glycemic variability in the 
logistic regression model since this variable had the low-
est p-value in the univariate analysis comparing patients 
with or without post-procedural MAE. This decision was 
made prior to statistical analysis considering the number 
of MAE observed. Discrimination and calibration of the 
model were tested using the Hosmer–Lemeshow test.
The relationships between the mean daily δ blood glu-
cose and, respectively, the number of adjustments made 
in the insulin infusion rate, the rate of insulin therapy 
adjustment, and the insulin infusion rate variability, were 
analyzed by using the Spearman-rank correlation coef-
ficient. The mean daily δ blood glucose was compared 
according to the preoperative glycosylated hemoglobin 
value ≥ 6.5% or < 6.5% [5] by using the Mann–Whit-
ney U-test. No subgroup or sensitivity analysis were 
conducted.
All statistical analyses were performed using SAS 9.4 
software (SAS Institute Inc., Cary, NC, USA). All p-val-
ues are two-sided and p < 0.05 was considered statistically 
significant. The post-study power was computed by using 
the Shieh-O’Brien approximation and estimated at 94%.
Results
During the study period, a total of 180 patients were 
included in the FRANCE or FRANCE-2 registries in our 
center, and 160 patients were analyzed in the present 
study (Fig.  1). The demographic characteristics of the 
study population are detailed in Table 1. TAVI was per-
formed via femoral route in 85 (53%) patients. A balloon-
expendable valve was implanted in 148 (92%) patients.
The primary endpoint occurred in 36 (22%) patients. 
Nine (6%) patients had 2 or more post-procedural 
MAEs. Baseline characteristics did not significantly dif-
fer between those who suffered an MAE and those who 
did not (Table 1). The rates of each event composing the 
primary outcome and of other complications (secondary 
outcomes) are given in Table 2. The length of stay in the 
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Cardiac Surgery ICU was significantly higher in patients 
with post-procedural MAE versus those without (4 [2–6] 
vs. 2 [1–3] days, p < 0.001).
Variables related to blood glucose control within the 
first 48 h after TAVI are presented in Table 3. The average 
blood glucose level, the percentage of blood glucose val-
ues within the target range of 4.4–8.2 mmol  l−1 and the 
rate of hyperglycemia or severe hypoglycemia were not 
different between patients who underwent post-proce-
dural MAE and those who did not (Table 3).
The glycemic variability, as assessed using mean daily δ 
blood glucose, SD of blood glucose or coefficient of vari-
ability, was significantly higher in patients with post-pro-
cedural MAE (Table 3). The median value of mean daily 
δ blood glucose was 4.3 mmol  l−1, and the 1st, 2nd, 3rd 
and 4th quartile of the mean daily δ blood glucose values 
were < 3.0, 3.0–4.3, 4.4–5.7, > 5.7  mmol  l−1, respectively. 
The proportion of MAE within 30  days after TAVI sig-
nificantly increased for each quartile of the mean daily 
δ blood glucose, from 12% and 12% in the 1st and 2nd 
quartiles to 26%, and 39% in the third, and fourth quar-
tiles, respectively (p = 0.002). The mean daily δ blood 
glucose did not significantly differ in patients present-
ing post-procedural atrial fibrillation (4.2 [3.0–5.7] vs 
4.3 [2.9–5.8] mmol  l−1, p = 0.93) and in patients suffer-
ing from acute renal failure (4.1 [2.5–5.8] vs 4.4 [3.2–5.7] 
mmol l−1, p = 0.34) within 30 days after TAVI.
By logistic regression, mean daily δ blood glucose was 
associated with an increased risk of post-procedural 
MAE within 30 days after TAVI (odds ratio [95% confi-
dence interval] per quartile: 1.83 [1.19–2.83]; p = 0.006) 
(Table 4).
The median number of adjustments made in the insulin 
infusion rate was 4 [2–6], and the median rate of insu-
lin therapy adjustment was 0.22 [0.14–0.33]. A statisti-
cally significant correlation was found between the mean 
daily δ blood glucose and (1) the number of adjustments 
made in the insulin infusion rate (Spearman δ = 0.543; 
p < 0.001); (2) the rate of insulin therapy adjustment 
(Spearman δ = 0.422; p < 0.001); and (3) the insulin infu-
sion rate variability (Spearman δ = 0.564; p < 0.001) 
(Fig. 2a, b). The mean daily δ blood glucose did not signif-
icantly differ according to the preoperative glycosylated 
hemoglobin (5.4 [3.2–7.1] versus 4.2 [2.9–5.6] mmol l−1, 
p = 0.06; in patients with preoperative glycosylated 
hemoglobin ≥ and < 6.5% respectively).
Discussion
Our results suggest that early post-procedural glycemic 
variability was associated with a higher risk for MAEs 
within 30 days after TAVI. In contrast, the average blood 
glucose value and the rate of hyperglycemic episodes 
within the first 2 days post-procedure were not found to 
be related to outcome.
Eligible patients 
n = 180 
Patients included 
n = 160  
Patients excluded: n = 20 
Intra-procedural death: n = 2 
Major complication within 48 hours 
after TAVI: n = 18 
major adverse event 
n = 36 
No major adverse event 
n = 124 
Fig. 1 Flow chart of the study population
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Glycemic variability and outcome
Long-term visit-to-visit glycemic variability was associ-
ated to both a higher risk of micro- and macrovascular 
complications and poor outcome after acute lung dis-
eases in type 2 diabetes mellitus patients [24–26]. The 
detrimental impact of short-term glycemic variability on 
the outcome of both diabetic and non-diabetic patients 
has been reported in various clinical situations [1, 2, 
27, 28]. In cardiac surgery patients, a strong association 
between glycemic variability and postoperative morbidity 
and mortality was reported after CABG but not after 
isolated aortic valve surgical repair [5, 6, 29]. This sug-
gests that several differences may exist between surgi-
cal aortic valve repair and TAVI, and deserves further 
analysis. First, TAVI patients included in the FRANCE 
and FRANCE-2 registries in our center were older (84 
[80–88] versus 67 [57–76] years), and had more asso-
ciated co morbidities and a higher rate of MAEs than 
patients who underwent cardiac surgery in the study by 
Bardia et al. [18, 19, 29]. This is also in accordance with 
Table 1 Baseline demographics and patient characteristics, in patients who underwent or not a post-procedural major 
adverse event
Data are number of patients (percentage)
BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; ECA, enzyme conversion antagonist; eGFR, estimated 
glomerular filtration rate; LVEF, left ventricular ejection fraction; MAE, major adverse event; NYHA, New York Heart Association; STS, Society of Thoracic Surgery
a Data are median [interquartile range 25–75%]
All patients (n = 160) MAE− (n = 124) MAE+ (n = 36) p value
Age (years)a 84 [80–88] 84 [81–88] 84 [79–87] 0.56
Male 79 (49) 60 (48) 19 (53) 0.64
Comorbidities
 Smoking 21 (13) 15 (12) 6 (17) 0.57
 Dyslipidemia 77 (48) 61 (49) 16 (44) 0.62
 Diabetes mellitus 41 (26) 32 (26) 9 (25) 1.00
 Hypertension 119 (74) 89 (72) 30 (83) 0.16
 Obesity (BMI ≥ 30 kg m−2) 25 (16) 23 (19) 2 (6) 0.07
 COPD 119 (74) 94 (76) 25 (69) 0.44
 Stroke 23 (14) 18 (15) 5 (14) 1.00
 Peripheral artery disease 22 (14) 16 (13) 6 (17) 0.59
Coronary artery disease 100 (62) 79 (64) 21 (58) 0.56
Medications
 Beta‑blockers 27 (17) 22 (18) 5 (14) 0.62
 ECA 55 (34) 42 (34) 13 (36) 0.94
 Statin 69 (43) 55 (44) 14 (39) 0.39
 Aspirin 71 (44) 55 (44) 16 (44) 0.82
 Clopidogrel 47 (29) 37 (30) 10 (28) 0.83
 Biguanides 9 (6) 9 (7) 0 (0) 0.12
 Insulin 8 (5) 6 (5) 2 (6) 1.00
Previous CABG 38 (24) 30 (24) 8 (22) 1.00
NYHA class III or IV 95 (59) 69 (56) 26 (72) 0.07
Pacemaker 23 (14) 16 (13) 7 (19) 0.42
Atrial fibrillation 38 (24) 31 (25) 7 (19) 0.66
Logistic Euroscore (%)a 20 [12–32] 20 [12–30] 26 [14–36] 0.09
Baseline eGFR (ml min−1 1.72 m−2)a 42 [30–58] 42 [29–60] 40 [30–46] 0.21
Preoperative blood glucose level (mmol l−1)a 5.3 [4.7–6.1] 5.3 [4.6–6.1] 5.2 [4.9–5.7] 0.83
Glycosylated hemoglobin (%)a 6.0 [5.5–6.8] 6.0 [5.5–6.8] 5.8 [5.5–6.5] 0.55
Left ventricular function 0.60
 Good (LVEF ≥ 50%) 108 (68) 86 (70) 22 (61)
 Fair (LVEF 30–49%) 47 (29) 34 (27) 13 (36)
 Poor (LVEF < 30%) 5 (3) 4 (3) 1 (3)
Mean transaortic gradient (mm Hg)a 49 [40–57] 49 [42–57] 46 [35–57] 0.40
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previously published data evaluating patient outcome 
after TAVI [12, 18, 30]. Second, less blood glucose level 
variations was reported in the study by Bardia et al. than 
in ours [29]. This may be related to differences in patient 
case-mix or in the way blood glucose was managed post-
operatively. It should be outlined that we observed a 
lower rate of MAEs among patients in the 2 first quartiles 
of glycemic variability, and increasing rates across the 
third and fourth quartiles, up to 44%. This is in accord-
ance with the results of Krinsley et  al. showing a link 
between the magnitude of blood glucose variability and 
outcome in ICU patients [27]. Lastly, recordings of blood 
glucose levels were limited to the first postoperative day 
in the study by Bardia et  al., and evolution of glycemic 
variability on postoperative day 2 was not known [29].
Parameters used to assess short‑term glycemic variability
Several variables have been proposed to characterize 
glycemic variability, but no gold standard has emerged 
from previous studies. The hyperglycemic index [31], the 
hypoglycemic index, the glycemic penalty index [32], or 
the jack-knife approximate entropy [2] are well-adapted 
to quantify glycemic variability over a long period in 
diabetic patients. We used three variables, namely the 
standard deviation of blood glucose value [31], the 
coefficient of variability of blood glucose [32], and the 
mean daily δ blood glucose [2], all previously described 
to assess glycemic variability after surgery or in ICU 
patients. All three variables were significantly higher in 
patients who presented an MAE after TAVI. We chose 
to include the mean daily δ blood glucose in the logistic 
regression model since the p-value for this parameter in 
Table 2 Rate of post-procedural adverse events
Data are number of patients (percentage)
Major adverse event is a composite endpoint including death from all causes, 
stroke, myocardial infarction, acute heart failure, and life-threatening ventricular 
arrhythmias
AKIN, Acute Kidney Injury Network classification, used for acute renal failure 
grading
All patients 
(n = 160)
Major adverse event 36 (22)
 Death 17 (11)
 Myocardial infarction 6 (4)
 Stroke 7 (4)
 Acute heart failure 12 (7)
 Life‑threatening cardiac arrhythmia 6 (4)
Other postoperative complication 60 (37)
 Atrial fibrillation 45 (28)
 Respiratory failure requiring mechanical ventilation 13 (8)
 Acute renal failure 50 (31)
  AKIN grade 1 31 (19)
  AKIN grade 2 4 (2)
  AKIN grade 3 15 (9)
Table 3 Comparison of blood glucose control parameters within the first 48 after TAVI between patients who underwent 
or not a post-procedural major adverse event
Data are number of patients (percentage)
MAE, major adverse event
a Data are median [interquartile range 25–75%]
b Hyperglycemia was defined as two consecutive blood glucose values ≥ 8.2 mmol l−1
c Moderate hypoglycemia was defined as a blood glucose value < 3.8 mmol l−1
d Severe hypoglycemia was defined as a blood glucose value < 2.2 mmol l−1
MAE− (n = 124) MAE+ (n = 36) p value
Blood glucose control parameters
 Number of blood glucose measurements per  patienta 16 [12–19] 18 [14–20] 0.03
 Average blood glucose value (mmol l−1)a 7.1 [6.6–7.8] 7.2 [6.5–8.1] 0.54
 Percentage of blood glucose values within 4.4–8.2 mmol l−1 67 [51–79] 58 [41–75] 0.08
 Hyperglycemiab 77 (62) 26 (72) 0.26
 Moderate  hypoglycemiac 20 (16) 9 (25) 0.23
 Severe  hypoglycemiad 3 (2) 2 (6) 0.31
Insulin consumption
 Total dose of insulin infused (IU/l)a 12 [4–19] 13 [3–30] 0.40
Glycemic variability
 Mean daily δ blood glucose (mmol l−1)a 4.0 [2.9–5.3] 5.4 [4.1–7.7] 0.001
 Standard deviation of blood glucose value (mmol l−1)a 1.6 [1.1–2.0] 1.8 [1.5–2.4] 0.01
 Coefficient of variability of blood glucose (%)a 22 [17–27] 24 [22–34] 0.007
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the univariate analysis was the lowest among the differ-
ent glycemic variables examined. Moreover, the mean 
daily δ blood glucose could appear as the simplest varia-
ble to appreciate glycemic variability at the bedside in the 
absence of continuous glucose monitoring system.
Underlying mechanisms for increased glycemic variability
Several factors have been reported to increased blood 
glucose variability, such as poorly-controlled diabetes 
mellitus or the degree of activation of the autonomic 
nervous system [33, 34]. We observed a significant but 
weak correlation between the mean daily δ blood glucose 
and both the number of insulin rate adjustments and 
the insulin infusion rate variability. These differences in 
blood glucose management could be a part of the mecha-
nisms involved in, but also simply the consequences of 
increased glycemic variability.
Limits of the study
The present study has several limitations. First, it was a 
single center study with relatively small sample size that 
could limit the external validity of the results observed. 
However, the baseline characteristics of the patients, 
the rate of complications and the mortality observed 
in this cohort were similar to the data reported in the 
entire cohort of the FRANCE and FRANCE-2 registries 
[18, 19]. Moreover, the values of the parameters used to 
assess glycemic variability observed in our cohort were 
similar to those reported in previously published studies 
[2, 6]. The sample size did not allow for subgroup analy-
sis to differentiate outcome in either diabetic or non-
diabetic patients and this question should be addressed 
in a specifically designed study. The sample size could 
also explain that the trend observed between the risk of 
MAEs and the Euroscore value did not reach the statis-
tical significance although a weak but statistically sig-
nificant association was reported between Euroscore 
and mortality after TAVI in some previously published 
studies [35, 36]. Second, glycemic variability was not 
determined using a continuous monitoring system and 
could be underestimated [3]. The present study is based 
on a posthoc analysis of data from patients included in 
Table 4 Multivariable analysis of  factors associated 
with  an  increased risk for  major adverse event 
within 30 days after TAVI
Chi2 = 6.13, p = 0.63 for the Hosmer–Lemeshow goodness-of-fit test
BMI, body mass index; NYHA, New York Heart Association; OR [95% CI], odds 
ratio [95% confidence interval]
a Study population divided into 4 equal groups according to the quartile 
of mean daily δ blood glucose defined by values < 3.0, 3.0–4.3, 4.4–
5.7, > 5.7 mmol l−1, respectively
b Post-procedural hyperglycemia was defined as two consecutive blood glucose 
values ≥ 8.2 mmol l−1
OR [95% CI] p value
Mean daily δ blood glucose, per  quartilea 1.83 [1.19–2.83] 0.006
Hyperglycemiab 0.84 [0.31–2.27] 0.73
Logistic EuroSCORE (per % of increase) 1.03 [0.99–1.06] 0.12
NYHA class III or IV 2.00 [0.83–4.81] 0.12
Obesity (BMI ≥ 30 kg m−2) 0.22 [0.05–1.05] 0.06
Hypertension 1.64 [0.57–4.72] 0.36
Fig. 2 Glycemic variability and insulin therapy adjustments. a Relationship between mean daily δ blood glucose and the number of adjustments 
made in the insulin infusion rate. b Relationship between mean daily δ blood glucose and the rate of insulin therapy adjustments
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the FRANCE and FRANCE-2 registries and continuous 
glucose monitoring is not our current practice in TAVI 
patients. Third, we used a composite parameter as the 
primary outcome to increase the power of the study. The 
choice of the events defining the primary outcome was 
based on their common potential impact on the progno-
sis of these patients. Fourth, we calculated a high post-
study power, but potential unidentified confounding 
factor could not be excluded. Moreover, the power of the 
study could also be appropriately appreciated by analyz-
ing the width and the magnitude of the 95% confidence 
intervals. Fifth, glycemic variability after discharge from 
the ICU was not measured and could have impacted dif-
ferently the prognosis of these patients.
Conclusions
Post-procedural glycemic variability could be associated 
with an increased risk of major adverse events within 
30  days after TAVI. This observation needs to be con-
firmed in a specifically designed study involving a con-
tinuous glucose monitoring system. Glycemic variability 
could be a new dimension in the management of blood 
glucose after TAVI. Further investigations are warranted 
to identify the underlying mechanisms that contribute 
to increased glycemic variability and could represent a 
new therapeutic target to prevent wide variations in early 
post-procedure blood glucose levels.
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